Yasuhiro Mouri

Dr. Yasuhiro Mouri


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2024 in Journal of Oral Biosciences
Verified
Journal Article
Closed access
KYKayo Yoshida
Kayo Yoshida
YMYasuhiro Mouri
Yasuhiro Mouri
ATAyu Takai
Ayu Takai
MSMariko Seyama
Mariko Seyama
MMMana Mekata
Mana Mekata
KOKazumi Ozaki
Kazumi Ozaki

30 June 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GOGO OHE
GO OHE
Yasusei KudoYasusei Kudo
Yasusei Kudo
KKKumiko Kamada
Kumiko Kamada
YMYasuhiro Mouri
Yasuhiro Mouri
NTNatsumi Takamaru
Natsumi Takamaru
YMYouji Miyamoto
Youji Miyamoto
(1) Background: OK-432 is a penicillin-killed, lyophilized formulation of a low-toxicity strain (Su) of Streptococcus pyogenes (Group A). It is a potent immunotherapy agent for several types of cancer, including oral cancer. We previously showed that (i) OK-432 treatment induces a high amount of IFN-γ production from peripheral blood mononuclear cells (PBMCs), and (ii) conditioned medium (CM) from oral cancer cells suppresses both the IFN-γ production and cytotoxic activity of PBMCs driven by OK-432. The aim of this study was to determine the inhibitory mechanism of OK-432-induced IFN-γ production from PBMCs by CM. (2) Methods: We performed cDNA microarray analysis, quantitative RT-PCR, and ELISA to reveal the inhibitory mechanism of CM. (3) Results: We found that CD40 plays a key role in IFN-γ production via IL-12 production. Although OK-432 treatment upregulated the expression levels of the IL-12p40, p35, and CD40 genes, CM from oral cancer cells downregulate these genes. The amount of IFN-γ production by OK-432 treatment was decreased by an anti-CD40 neutralizing antibody. (4) Conclusions: Our study suggests that uncertain soluble factor(s) produced from oral cancer cells may inhibit IFN-γ production from PBMCs via suppressing the CD40/CD40L–IL-12 axis.

15 August 2026 in Oncogene
Verified
Journal Article
Closed access
PDF file
ZLZichao Lu
Zichao Lu
YMYasuhiro Mouri
Yasuhiro Mouri
WSWenhua Shao
Wenhua Shao
AYAkihiro Yasue
Akihiro Yasue
CWChunhua Wang
Chunhua Wang
Yasusei KudoYasusei Kudo
Yasusei Kudo